These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 36036525)
1. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. Connolly SJ; Karthikeyan G; Ntsekhe M; Haileamlak A; El Sayed A; El Ghamrawy A; Damasceno A; Avezum A; Dans AML; Gitura B; Hu D; Kamanzi ER; Maklady F; Fana G; Gonzalez-Hermosillo JA; Musuku J; Kazmi K; Zühlke L; Gondwe L; Ma C; Paniagua M; Ogah OS; Molefe-Baikai OJ; Lwabi P; Chillo P; Sharma SK; Cabral TTJ; Tarhuni WM; Benz A; van Eikels M; Krol A; Pattath D; Balasubramanian K; Rangarajan S; Ramasundarahettige C; Mayosi B; Yusuf S; N Engl J Med; 2022 Sep; 387(11):978-988. PubMed ID: 36036525 [TBL] [Abstract][Full Text] [Related]
2. The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. Karthikeyan G; Connolly SJ; Ntsekhe M; Benz A; Rangarajan S; Lewis G; Yun Y; Sharma SK; Maklady F; Elghamrawy AE; Kazmi K; Cabral TTJ; Dayi H; Changsheng M; Gitura BM; Avezum A; Zuhlke L; Lwabi P; Haileamlak A; Ogah O; Chillo P; Paniagua M; ElSayed A; Dans A; Gondwe-Chunda L; Molefe-Baikai OJ; Gonzalez-Hermosillo JA; Hakim J; Damasceno A; Kamanzi ER; Musuku J; Davletov K; Connolly K; Mayosi BM; Yusuf S; Am Heart J; 2020 Jul; 225():69-77. PubMed ID: 32474206 [TBL] [Abstract][Full Text] [Related]
3. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. Guimarães HP; Lopes RD; de Barros E Silva PGM; Liporace IL; Sampaio RO; Tarasoutchi F; Hoffmann-Filho CR; de Lemos Soares Patriota R; Leiria TLL; Lamprea D; Precoma DB; Atik FA; Silveira FS; Farias FR; Barreto DO; Almeida AP; Zilli AC; de Souza Neto JD; Cavalcante MA; Figueira FAMS; Kojima FCS; Damiani L; Santos RHN; Valeis N; Campos VB; Saraiva JFK; Fonseca FH; Pinto IM; Magalhães CC; Ferreira JFM; Alexander JH; Pavanello R; Cavalcanti AB; Berwanger O; N Engl J Med; 2020 Nov; 383(22):2117-2126. PubMed ID: 33196155 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA; Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454 [TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Mahaffey KW; Wojdyla D; Hankey GJ; White HD; Nessel CC; Piccini JP; Patel MR; Berkowitz SD; Becker RC; Halperin JL; Singer DE; Califf RM; Fox KA; Breithardt G; Hacke W Ann Intern Med; 2013 Jun; 158(12):861-8. PubMed ID: 23778903 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338 [TBL] [Abstract][Full Text] [Related]
7. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. Gibson CM; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Birmingham M; Ianus J; Burton P; van Eickels M; Korjian S; Daaboul Y; Lip GY; Cohen M; Husted S; Peterson ED; Fox KA N Engl J Med; 2016 Dec; 375(25):2423-2434. PubMed ID: 27959713 [TBL] [Abstract][Full Text] [Related]
8. Thromboembolism, bleeding and vascular death in nonvalvular atrial fibrillation patients with type 2 diabetes receiving rivaroxaban or warfarin. Coleman CI; Costa OS; Brescia CW; Vardar B; Abdelgawwad K; Sood N Cardiovasc Diabetol; 2021 Feb; 20(1):52. PubMed ID: 33637082 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis Patients with Atrial Fibrillation: A Multicenter Randomized Controlled Trial. De Vriese AS; Caluwé R; Van Der Meersch H; De Boeck K; De Bacquer D J Am Soc Nephrol; 2021 Jun; 32(6):1474-1483. PubMed ID: 33753537 [TBL] [Abstract][Full Text] [Related]
10. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR; Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435 [TBL] [Abstract][Full Text] [Related]
11. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial. Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM Circ Cardiovasc Interv; 2019 Nov; 12(11):e008160. PubMed ID: 31707805 [TBL] [Abstract][Full Text] [Related]
12. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. Van Mieghem NM; Unverdorben M; Hengstenberg C; Möllmann H; Mehran R; López-Otero D; Nombela-Franco L; Moreno R; Nordbeck P; Thiele H; Lang I; Zamorano JL; Shawl F; Yamamoto M; Watanabe Y; Hayashida K; Hambrecht R; Meincke F; Vranckx P; Jin J; Boersma E; Rodés-Cabau J; Ohlmann P; Capranzano P; Kim HS; Pilgrim T; Anderson R; Baber U; Duggal A; Laeis P; Lanz H; Chen C; Valgimigli M; Veltkamp R; Saito S; Dangas GD; N Engl J Med; 2021 Dec; 385(23):2150-2160. PubMed ID: 34449183 [TBL] [Abstract][Full Text] [Related]
13. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC; Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831 [TBL] [Abstract][Full Text] [Related]
15. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Kerneis M; Yee MK; Mehran R; Nafee T; Bode C; Halperin JL; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Cohen M; Fox KAA; Gibson CM Circ Cardiovasc Interv; 2019 Feb; 12(2):e007124. PubMed ID: 30704287 [TBL] [Abstract][Full Text] [Related]
16. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study. Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582 [TBL] [Abstract][Full Text] [Related]
20. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ; J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]